Advert - Janssen-Cilag Ltd – Case AUTH/3436/12/20

Nurse led Stelara homecare service


Janssen voluntarily admitted that it had failed to maintain oversight and high standards in relation to a nurse-led Stelara (ustekinumab) homecare service and was ruled in breach of the following clauses of the 2019 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 9.1 - Failing to maintain high standards

In addition, the Code of Practice Appeal Board required Janssen to be publicly reprimanded for its failure to have oversight or control of a patient-facing service for 28 months and for its delay in making its voluntary admission once the errors had come to the company’s attention; the company was also required to be audited and re-audited.